{"id":"ammoxetine-hydrochloride-enteric-coated-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by increasing the levels of norepinephrine in the brain, which can help improve symptoms of attention deficit hyperactivity disorder (ADHD).","oneSentence":"Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:26.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention deficit hyperactivity disorder (ADHD)"}]},"trialDetails":[{"nctId":"NCT06827431","phase":"PHASE3","title":"The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-02-14","conditions":"Major Depressive Disorder (MDD)","enrollment":770},{"nctId":"NCT05762458","phase":"PHASE2","title":"The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-02-28","conditions":"Major Depressive Disorder (MDD)","enrollment":240},{"nctId":"NCT05018013","phase":"PHASE2","title":"Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-08-21","conditions":"Major Depressive Disorder (MDD)","enrollment":240},{"nctId":"NCT03850834","phase":"PHASE1","title":"Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2019-03-10","conditions":"Depression","enrollment":36},{"nctId":"NCT03456388","phase":"PHASE1","title":"Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2017-10-30","conditions":"Depression","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ammoxetine"],"phase":"phase_2","status":"active","brandName":"Ammoxetine Hydrochloride Enteric-coated Tablets","genericName":"Ammoxetine Hydrochloride Enteric-coated Tablets","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ammoxetine hydrochloride is a norepinephrine reuptake inhibitor. Used for Attention deficit hyperactivity disorder (ADHD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}